Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -13.37% is 45% above its 5-year average of -24.14%, around the middle of its 5-year range (-99.94%–47.94%).
199.88% below its 12-month average of -4.46%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2027 (2026-06-30): -64.35%.
EBITDA MARGIN
-13.37%
EBITDA MARGIN AVG TTM
-4.46%
EBITDA MARGIN AVG 3Y
6.13%
EBITDA MARGIN AVG 5Y
-24.14%
EBITDA MARGIN AVG 10Y
-57.97%
EBITDA MARGIN AVG 15Y
-57.97%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-199.88%
CURRENT VS 3Y AVG
-318.01%
CURRENT VS 5Y AVG
+44.62%
CURRENT VS 10Y AVG
+76.94%
CURRENT VS 15Y AVG
+76.94%
CURRENT VS 20Y AVG
N/A
Aurora Cannabis Inc.
Market Cap
$284.31M
EBITDA Margin
-13.37%
TTM Avg
-4.46%
3Y Avg
6.13%
5Y Avg
-24.14%
Market Cap
$285.42M
EBITDA Margin
-1537.00%
TTM Avg
-1537.00%
3Y Avg
-1537.00%
5Y Avg
-1537.00%
Market Cap
$285.55M
EBITDA Margin
-1475.69%
TTM Avg
-1475.69%
3Y Avg
-2002.71%
5Y Avg
-1922.41%
Market Cap
$282.64M
EBITDA Margin
-101.16%
TTM Avg
-95.97%
3Y Avg
-88.25%
5Y Avg
-69.69%
Market Cap
$281.54M
EBITDA Margin
-25.38%
TTM Avg
-1946.60%
3Y Avg
-1509.96%
5Y Avg
-1364.90%
Market Cap
$280.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$292.59M
EBITDA Margin
-144.24%
TTM Avg
-144.24%
3Y Avg
-144.24%
5Y Avg
-144.24%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurora Cannabis Inc. (ACB) | $284.31M | -13.37% | -4.46% | 6.13% | -24.14% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | -1537.00% | -1537.00% | -1537.00% | -1537.00% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -1475.69% | -1475.69% | -2002.71% | -1922.41% |
| Standard BioTools Inc. (LAB)vs › | $282.64M | -101.16% | -95.97% | -88.25% | -69.69% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | -25.38% | -1946.60% | -1509.96% | -1364.90% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | -144.24% | -144.24% | -144.24% | -144.24% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | -64.44% | -40.40% | -20.73% | -9.01% |
Gross Margin
42.6%
EBITDA Margin
-13.4%
Operating Margin
-14.6%
Net Margin
-38.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -64.35% |
| 2025-12-31 | 11.89% |
| 2025-09-30 | -13.32% |
| 2025-06-30 | 47.94% |
| 2025-03-31 | -26.99% |
| 2024-12-31 | 47.94% |
| 2024-09-30 | 3.74% |
| 2024-06-30 | 7.93% |
| 2024-03-31 | 14.90% |
| 2023-12-31 | -15.33% |
| 2023-09-30 | -5.22% |
| 2023-06-30 | -6.02% |
| 2023-03-31 | -13.63% |
| 2022-12-31 | -96.29% |
| 2022-09-30 | -89.04% |
| 2022-06-30 | -85.25% |
| 2022-03-31 | -99.94% |
| 2021-12-31 | -49.16% |
| 2021-09-30 | -24.60% |
| 2021-06-30 | -28.04% |
| 2021-03-31 | -215.94% |
| 2020-12-31 | -39.08% |
| 2020-09-30 | -10.08% |
| 2020-06-30 | -255.65% |
| 2020-03-31 | -75.66% |
| 2019-12-31 | -167.17% |
| 2019-09-30 | -65.52% |
| 2019-06-30 | -27.96% |
| 2019-03-31 | -74.04% |
| 2018-12-31 | -100.10% |
| 2018-09-30 | -323.01% |
| 2018-06-30 | -192.69% |
| 2018-03-31 | -184.24% |
| 2017-12-31 | -131.47% |
| 2017-09-30 | -7.78% |
| 2017-06-30 | -56.82% |
| 2017-03-31 | -29.97% |
| 2016-12-31 | -53.17% |
| 2016-09-30 | -101.47% |
| 2016-06-30 | -186.94% |
| 2016-03-31 | 1285.54% |
| 2009-06-30 | 39.96% |
